DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus

Information source: Novartis
Information obtained from ClinicalTrials.gov on December 08, 2011
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: Aliskiren/Valsartan (Drug); Valsartan (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: Novartis

Official(s) and/or principal investigator(s):
Novartis, Study Director, Affiliation: Novartis

Overall contact:
Novartis, Phone: 862-778-8300

Summary

The purpose of the study is to evaluate the blood pressure (BP)-lowering efficacy of the combination of aliskiren and valsartan, as initial therapy, compared to valsartan monotherapy in Type II Diabetic patients with Stage II hypertension.

Clinical Details

Official title: An 8 Week Randomized, Double-Blind, Parallel Group, Multi-Center, Active Controlled Study to Evaluate the Antihypertensive Efficacy and Safety of Aliskiren Administered in Combination With Valsartan Versus Valsartan Alone in Patients With Stage 2 Systolic Hypertension and Type 2 Diabetes Mellitus

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: Change from baseline in MSSBP

Secondary outcome:

Change from baseline in MSDBP

Percentage of patients achieving BP control (defined as MSSBP < 130 mmHg and MSDBP <80)

Percentage of responders (defined as patients with MSSBP <130 mmHg or a reduction from baseline in MSSBP of >20 mmHg)

Change in MSSBP in patients with baseline MSSBP ≥180 mmHg and <200 mmHg and Type 2 diabetes mellitus

Safety and tolerability of the combination of aliskiren and valsartan versus valsartan monotherapy

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients who are eligible and able to participate in the study, and who give written

informed consent before any assessment is performed.

- Men or women 18 years and older.

- Patients with Stage 2 systolic hypertension, defined as having a MSSBP ≥160 mmHg and

<200 mmHg at Visit 5 (randomization).

- Patients who have been newly diagnosed with hypertension or who have not received

antihypertensive medication for at least 4 weeks (28 days) prior to Visit 1 must have MSSBP ≥ 160 mmHg and < 200 mmHg at Visit 1, otherwise, they will be considered screen failures.

- Patients receiving antihypertensive medication must have a MSSBP of ≥150 mmHg and

<200 mmHg at Study Visit 1, otherwise they will be considered screen failures.

- Patients with Type 2 diabetes mellitus with an HbA1c ≤ 9 % at visit 1 and on a stable

anti-diabetic regimen not including insulin or stable diet and exercise for at least 4 weeks prior to visit 1.

Exclusion Criteria:

- Office blood pressure measured by cuff (MSSBP ≥200 mmHg or MSDBP ≥120 mmHg).

- History or evidence of secondary hypertension of any etiology.

- Refractory hypertension, defined as having uncontrolled BP (≥140/90 mmHg) while

receiving 3 antihypertensive medications at the maximum approved dose of each drug, one of which must be a diuretic.

- Patients treated with more than 3 antihypertensive medications (each component of a

combination drug counts individually).

- Type 2 diabetes mellitus currently requiring insulin treatment.

- MDRD estimated GFR (eGFR) < 60 mL/min/1. 73m2

- Serum sodium less than lower limit of normal, serum potassium < 3. 5 mEq/L or ≥ 5. 3

mEq/L at Visit 1.

- Known Keith-Wagener grade III or IV hypertensive retinopathy.

- Other protocol-defined inclusion/exclusion criteria may apply.

Locations and Contacts

Novartis, Phone: 862-778-8300

Investigative Site, Newark, Delaware USA, United States; Recruiting
Novartis, Phone: 862-778-8300

Investigative Site, Kansas, Missouri, United States; Recruiting
Novartis, Phone: 862-778-8300

Investigative Site, Camden, New Jersey, United States; Recruiting
Novartis, Phone: 862-778-8300

Investigative Site, Philadelphia, Pennsylvania, United States; Recruiting
Novartis, Phone: 862-778-8300

Additional Information

Starting date: May 2009
Last updated: March 31, 2011

Page last updated: December 08, 2011

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014